The most recent Phase 2 results reveal that NS002 has shown promise in delivering epinephrine more effectively than EpiPen®. The findings indicate statistically significant enhancements in early absorption. A crucial pivotal study is scheduled for the fourth quarter of 2026, highlighting the product's potential as a leading option for epinephrine delivery.